BioCryst Pharmaceuticals Inc.
BCRX | NASDAQ
$8.81
+$0.05 (+0.57%)
Sep 22, 2026, 2:03 PM ET · Market open
Market Data
Market Cap $2.23B
Enterprise Value $2.28B
Beta 0.56
Average Volume 4.37M
Shares Outstanding (Diluted) 265.17M
Shares Change YoY 20.59%
Institutional Ownership N/A
Exchange NASDAQ
ISIN US09058V1035
Price Performance
Price Change 1M -7.8%
Price Change 3M -5.9%
Price Change 6M -6.8%
Price Change YTD 16.8%
Price Change 1Y 10.8%
Price Change 3Y 19.2%
Price Change 5Y -41.3%
1M CAGR (ann.) -6.6%
1Y CAGR (ann.) 10.1%
5Y CAGR (ann.) -10.8%
All-Time CAGR -1.3%
Valuation
PE Ratio -5.84
Forward PE 19.50
PEG Ratio 0.00
Forward PEG 0.05
PS Ratio 2.37
Forward PS 3.00
PB Ratio -4.90
P/FCF Ratio 6.22
P/Adj. FCF Ratio 9.43
P/OCF Ratio 6.21
EV/Sales 2.43
EV/EBIT -7.39
EV/EBITDA -7.54
EV/FCF 6.38
Earnings Yield -17.1%
FCF Yield 16.1%
Adj. FCF Yield 10.6%
Financial Health
Net Debt $42.83M
Total Debt $409.86M
Cash & Short-Term Investments $352.57M
Total Assets $557.85M
Current Ratio 2.32
Quick Ratio 2.29
Debt / Equity Ratio -0.90
Debt / EBITDA -1.35
Debt / FCF 1.14
OCF / Debt 0.88
Interest Coverage -4.16
Altman Z-Score -3.62
Piotroski F-Score 5
Margins & Profitability
Gross Profit Margin 23.5%
Operating Profit Margin -33.3%
EBITDA Margin -32.2%
Net Profit Margin -40.9%
FCF Margin 38.1%
Adj. FCF Margin 25.1%
SBC / Revenue 13.0%
SBC Impact (per share) -34.0%
Returns
Return on Assets -69.0%
Return on Equity 101.5%
Return on Invested Capital -89.0%
Return on Capital Employed -89.7%
Return on Tangible Assets -69.0%
Historical Growth (CAGR)
Revenue CAGR 3Y 45.3%
Revenue CAGR 5Y 64.1%
Revenue CAGR 10Y 43.6%
EPS CAGR 3Y -47.9%
EPS CAGR 5Y 4.2%
EPS CAGR 10Y -1.6%
FCF CAGR 3Y 231.2%
FCF CAGR 5Y 88788.9%
FCF CAGR 10Y 53.2%
Analyst Forecasts
Analyst Rating Buy
Analyst Count 29
EPS Growth Next 3Y 56.0%
Revenue Growth Next 3Y 1.4%
Earnings Date Nov 1, 2026
EPS Estimate (next Q) $0.10
EPS Growth Est (next Q) 66.7%
Revenue Est (next Q) $165.37M
Revenue Growth Est (next Q) 3.8%
Fair Value Estimates
Graham Number N/A
Graham Upside N/A
Lynch Fair Value N/A
Lynch Upside N/A
Price Target $19
Price Target Upside 116.9%
Cash Flow
Operating Cash Flow $360.21M
Free Cash Flow $358.07M
Adj. Free Cash Flow $236.18M
FCF Per Share $1.40
OCF Per Share $1.41
OCF/S Ratio 38.3%
Income Statement
Revenue $940.61M
Gross Profit $221.2M
Operating Income $-313.16M
EBITDA $-302.87M
Net Income $-384.67M
EPS (Diluted) -$1.50
Revenue / Employee $2.16M
Profit / Employee $-884.31K
Employees 435
Add to Watchlist
Select watchlists to add or remove BCRX